Q2pharma

Q2pharma specializes in developing small-molecule drugs against multi-drug resistant (MDR) bacteria to be used in conjunction with commonly used antibiotics or as stand-alone medications. Our lead compound, F19 has shown promise in combating deadly MDR bacterial infections. Whereas antibiotics kill bacteria, as an antivirulent, F19 inhibits bacterial toxin release and thus, stops the bacterial attack, allowing the immune system to do its job more effectively. F19 has been shown to potentiate antibiotic efficacy, even to antibiotics that the pathogen is otherwise resistant. Recent experiments have demonstrated F19’s potent effects on several of the most common and deadly MDR bacteria.